Chronic Hepatitis Delta: BJT-778 vs Bulevirtide

We are studying a new treatment called brelovitug for chronic hepatitis delta infection to see if it works better and is safer than the current treatment, bulevirtide. We also want to understand how it affects patients' quality of life.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Bulevirtide
Bulevirtide is a substance that prevents hepatitis B and D viruses from entering liver cells to help manage chronic hepatitis D.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

Bjt-778

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Medical University of Graz
Internal Medicine
Graz, Austria
Medical University Innsbruck
Internal Medicine 1
Innsbruck, Austria
Fakultni Nemocnice Brno
Klinika infekčních chorob
Brno, Czechia

Sponsor: Bluejay Therapeutics Inc.
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.